TY - JOUR
KW - Adult
KW - Aryl Hydrocarbon Hydroxylases/metabolism
KW - Buprenorphine/administration & dosage/adverse effects
KW - Cytochrome P-450 CYP2B6
KW - Cytochrome P-450 CYP2D6/metabolism
KW - Drug Therapy, Combination
KW - Evidence-Based Medicine
KW - Genetic Variation
KW - Humans
KW - Methadone/administration & dosage/adverse effects
KW - Narcotic Antagonists/administration & dosage/adverse effects
KW - Narcotics/adverse effects
KW - Opiate Substitution Treatment/methods
KW - Opioid-Related Disorders/epidemiology/metabolism/therapy
KW - Oxidoreductases, N-Demethylating/metabolism
KW - Psychotherapy
KW - Receptors, Opioid/genetics/metabolism
KW - Social Support
KW - Standard of Care
KW - Substance Withdrawal Syndrome/therapy
AU - M. Soyka
AU - H. R. Kranzler
AU - W. van den Brink
AU - J. Krystal
AU - H. J. Moller
AU - S. Kasper
AU - Guidelines for Substance Use Disorders WFSBP Task Force on Treatment
A1 - 
AB - OBJECTIVES: To develop evidence-based practice guidelines for the pharmacological treatment of opioid abuse and dependence. METHODS: An international task force of the World Federation of Societies of Biological Psychiatry (WFSBP) developed these practice guidelines after a systematic review of the available evidence pertaining to the treatment of opioid dependence. On the basis of the evidence, the Task Force reached a consensus on practice recommendations, which are intended to be clinically and scientifically meaningful for physicians who treat adults with opioid dependence. The data used to develop these guidelines were extracted primarily from national treatment guidelines for opioid use disorders, as well as from meta-analyses, reviews, and publications of randomized clinical trials on the efficacy of pharmacological and other biological treatments for these disorders. Publications were identified by searching the MEDLINE database and the Cochrane Library. The literature was evaluated with respect to the strength of evidence for efficacy, which was categorized into one of six levels (A-F). RESULTS: There is an excellent evidence base supporting the efficacy of methadone and buprenorphine or the combination of buprenorphine and naloxone for the treatment of opioid withdrawal, with clonidine and lofexidine as secondary or adjunctive medications. Opioid maintenance with methadone and buprenorphine is the best-studied and most effective treatment for opioid dependence, with heroin and naltrexone as second-line medications. CONCLUSIONS: There is enough high quality data to formulate evidence-based guidelines for the treatment of opioid abuse and dependence. This task force report provides evidence for the efficacy of a number of medications to treat opioid abuse and dependence, particularly the opioid agonists methadone or buprenorphine. These medications have great relevance for clinical practice.
BT - The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
C5 - Opioids & Substance Use; Education & Workforce
CP - 3
CY - England
DO - 10.3109/15622975.2011.561872
IS - 3
JF - The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
N2 - OBJECTIVES: To develop evidence-based practice guidelines for the pharmacological treatment of opioid abuse and dependence. METHODS: An international task force of the World Federation of Societies of Biological Psychiatry (WFSBP) developed these practice guidelines after a systematic review of the available evidence pertaining to the treatment of opioid dependence. On the basis of the evidence, the Task Force reached a consensus on practice recommendations, which are intended to be clinically and scientifically meaningful for physicians who treat adults with opioid dependence. The data used to develop these guidelines were extracted primarily from national treatment guidelines for opioid use disorders, as well as from meta-analyses, reviews, and publications of randomized clinical trials on the efficacy of pharmacological and other biological treatments for these disorders. Publications were identified by searching the MEDLINE database and the Cochrane Library. The literature was evaluated with respect to the strength of evidence for efficacy, which was categorized into one of six levels (A-F). RESULTS: There is an excellent evidence base supporting the efficacy of methadone and buprenorphine or the combination of buprenorphine and naloxone for the treatment of opioid withdrawal, with clonidine and lofexidine as secondary or adjunctive medications. Opioid maintenance with methadone and buprenorphine is the best-studied and most effective treatment for opioid dependence, with heroin and naltrexone as second-line medications. CONCLUSIONS: There is enough high quality data to formulate evidence-based guidelines for the treatment of opioid abuse and dependence. This task force report provides evidence for the efficacy of a number of medications to treat opioid abuse and dependence, particularly the opioid agonists methadone or buprenorphine. These medications have great relevance for clinical practice.
PP - England
PY - 2011
SN - 1814-1412; 1562-2975
SP - 160
EP - 187
EP - 
T1 - The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence
T2 - The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
TI - The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence
U1 - Opioids & Substance Use; Education & Workforce
U2 - 21486104
U3 - 10.3109/15622975.2011.561872
VL - 12
VO - 1814-1412; 1562-2975
Y1 - 2011
ER -